Pascal Borderies

Pascal Borderies serves as a Medical Advisor at DeepLife since April 2025, focusing on the application of Artificial Intelligence and in-silico methods in drug development. Previously, Borderies held significant leadership roles at BioXcel Therapeutics, Inc. from May 2018 to May 2024, including Vice President of Immuno-Oncology and Medical & Scientific Affairs, where responsibilities included leading the development of the oral immune activator BXCL701 and overseeing clinical studies. Additionally, Borderies contributed to the successful FDA approval and launch of IGALMI for acute agitation. Prior experience includes serving as SVP of Medical Affairs and Chief Medical Officer at Vernalis Therapeutics, overseeing all medical functions for multiple therapeutic areas. Pascal Borderies holds an MD in Medicine from Université Paris-Est Créteil, earned between January 1977 and January 1990.